

APPENDIX IV – Data Tables

Table A1	National institutions supplying data	57
Table A2	Total population data, by country, 1999 - 2004	58
Table A3	Percentage age distribution of population, by country, 1999 – 2004 combined	59
Table A4	Confirmed, probable and confirmed, and laboratory-diagnosed, incidences (all per 100,000), by country 1999, 2003, 2004	60
Table A5	Number of cases of confirmed and probable laboratory-diagnosed (% culture-diagnosed) invasive meningococcal disease, by country, 1999 – 2004	61
Table A6	Incidence (per 100,000) of confirmed and probable culture-diagnosed cases of invasive meningococcal disease, by country, 1999 - 2004	62
Table A7	Incidence (per 100,000) of laboratory-diagnosed confirmed and probable cases of invasive meningococcal disease, by country, 1999 - 2004	63
Table A8	Age distribution (number and % distribution) of cases of confirmed and probable laboratory-diagnosed meningococcal disease, all countries, 1999 - 2004	64
Table A9	Age-specific incidence (per 100,000) of confirmed and probable laboratory-diagnosed meningococcal disease, by country, 2003	65
Table A10	Age-specific incidence (per 100,000) of confirmed and probable laboratory-diagnosed meningococcal disease, by country, 2004	66
Table A11	Serogroup distribution of cases of confirmed and probable laboratory-diagnosed meningococcal disease, by country, 2003	67
Table A12	Incidence (per 100,000) of confirmed and probable laboratory-diagnosed meningococcal disease, by serogroup and country, 2003	68
Table A13	Serogroup distribution of cases of confirmed and probable laboratory-diagnosed meningococcal disease, by country, 2004	69
Table A14	Incidence (per 100,000) of confirmed and probable laboratory-diagnosed meningococcal disease, by serogroup and country, 2004	70
Table A15	Age distribution of cases of confirmed and probable laboratory-diagnosed serogroup B meningococcal disease, all countries, 1999 – 2004	71
Table A16	Age distribution of cases of confirmed and probable laboratory-diagnosed serogroup C meningococcal disease, all countries, 1999 – 2004	72
Table A17	Percentage distribution of confirmed and probable laboratory-diagnosed cases due to serogroup C, by country (total serogrouped cases), 1999 - 2004	73
Table A18	Dominant serotype of confirmed and probable laboratory-diagnosed serogroup C invasive meningococcal disease (number of serogroup C cases), by country, 1999 - 2004	74
Table A19	Dominant serotype of confirmed and probable laboratory-diagnosed serogroup B invasive meningococcal disease (number of serogroup B cases), by country, 1999 – 2004	75
Table A20	<i>Number of cases of phenotype B:P2.2a or B:P2.2b in sentinel countries involved in the rapid surveillance project by year and month, 1999-2004</i>	76
Table A21	Frequency of phenotype/genotype present in invasive meningococcal serogroup C isolates, by country, 2003	78

Table A22	Frequency of phenotype/genotype present in invasive meningococcal serogroup C isolates, by country, 2004	79
Table A23	Frequency of serosubtypes present in invasive meningococcal serogroup B isolates, by country, 2003	80
Table A24	Frequency of serosubtypes present in invasive meningococcal serogroup B isolates, by country, 2004	82
Table A25	Case fatality ratio in confirmed and probable laboratory-diagnosed cases of meningococcal disease, by country, 1999 – 2004	84
Table A26	Serogroup-specific case fatality rate in confirmed and probable laboratory-diagnosed cases of meningococcal disease, by country, 1999 – 2004 combined	85
Table A27	Proportion of meningitis in confirmed and probable laboratory-diagnosed cases of invasive meningococcal disease, 1999 – 2004	86

Table A1 National institutions supplying data

Country	Epidemiology/Surveillance Centre	Laboratory Reference/Microbiology Centre
Austria	General Directorate Public Health, Vienna	Austrian Agency for Food and Health Safety, Graz
Belgium	Epidemiology Section, Scientific Institute of Public Health, Brussels	National Meningococcal Reference Laboratory , Scientific Institute of Public Health, Brussels
Czech Republic	National Institute of Public Health, Prague	National Institute of Public Health, Prague
Denmark	Department of Epidemiology, Statens Serum Institut, Copenhagen	Department of Bacteriology, Mycology and Parasitology, Statens Serum Institut, Copenhagen
Estonia	Health Protectorate Inspectorate, Tallinn	Health Protectorate Inspectorate, Tallinn
Finland	Epidemiology, National Public Health Institute, Helsinki	Vaccine Immunology Laboratory, National Public Health Institute, Helsinki
France	Institut de Veille Sanitaire, Saint Maurice	Institut Pasteur, Paris
Germany*	Robert Koch Institute, Berlin	Institute for Hygiene and Microbiology, Würzburg
Greece	Public Health Department, National School of Public Health, Athens	National Meningococcal Reference Laboratory, National School of Public Health, Athens
Hungary	Johan Bela National Centre for Epidemiology, Budapest	Johan Bela National Centre for Epidemiology, Budapest
Iceland	Centre for Infectious Disease Control, Seltjarnarnes	Landspítali University Hospital, Reykjavik
Ireland	Health Protection Surveillance Centre, Dublin	Children's University Hospital, Dublin
Italy	Epidemiologia, Sorveglianza e Promozione della Salute, Istituto Superiore di Sanità, Rome	Department of Infectious, Parasitic and Immune-mediated Disease, Istituto Superiore di Sanità, Rome
Latvia	State Agency "Public Health Agency"	
Lithuania	Centre for Communicable Disease Prevention and Control, Vilnius	National Public Health Laboratory Center, Vilnius
Luxembourg	Inspection Sanitaire	Laboratoire National de Santé
Malta	Department of Public Health, Msida	
Netherlands	National Institute of Public Health and the Environment (RIVM), Bilthoven	Academic Medical Centre, Amsterdam
Norway	Norwegian Institute of Public Health, Oslo	Norwegian Institute of Public Health, Oslo
Poland	National Institute of Hygiene, Warsaw	National Institute of Public Health, Warsaw
Portugal	Direcção-Geral da Saúde, Lisbon	Instituto Nacional de Saúde Dr Ricardo Jorge, Lisbon
Slovak Republic	Section of Epidemiology, Public Health Authority, Bratislava	National Reference Centre for Meningococci, Public Health Authority, Bratislava
Slovenia	Communicable Diseases Centre, Institute of Public Health Slovenia, Ljubljana	Laboratory for Immunology and Molecular Diagnostics, National Reference Centre for Meningococci, Institute of Public Health Slovenia, Ljubljana
Spain	Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid	Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid
Sweden	Swedish Institute for Infectious Disease Control (SMI), Solna	Department of Clinical Microbiology and Immunology, Örebro
Switzerland	Swiss Federal Office of Public Health, Berne	Laboratoire Central de Bactériologie, Geneva
United Kingdom	Health Protection Agency, London / Stobhill Hospital, Glasgow	Manchester Medical Microbiology Partnership, Manchester / Stobhill Hospital, Glasgow

Countries with consistent data 1999 – 2004

*Data from Institute of Hygiene and Microbiology consistent across 1999 to 2004, used in serogroup and typing analyses; Robert Koch Institute data available only from 2001, used in all other analyses

Table A2 Total population data, by country, 1999 - 2004

Country	1999	2000	2001	2002	2003	2004	Source
Austria	8,094,156	8,113,413	8,131,690	8,148,312	8,162,656	8,174,762	www.census.gov/cgi-bin/ipc/idbagg (for Austria)
Belgium	10,226,419	10,251,250	10,286,570	10,332,785	10,376,133	10,421,137	www.iph.fgov.be/epidemi/spma/index.htm
Czech Republic	10,278,098	10,266,546	10,206,436	10,203,269	10,211,455	10,211,455	www.czso.cz/eng/edicniplan.nsf/t/79005D6975/\$File/40270301.pdf
Denmark	5,319,111	5,337,344	5,355,082	5,374,255	5,387,174	5,401,177	www.statbank.dk/statbank5a/default.asp?w=1024
Estonia	1,379,237	1,372,071	1,366,959	1,361,242	1,356,045	1,351,069	http://pub.stat.ee/px-web.2001/I_Databas/Population/Population.asp
Finland	5,158,097	5,168,595	5,180,309	5,193,039	5,204,405	5,214,512	www.census.gov/cgi-bin/ipc/idbagg (for Finland)
France	60,158,533	60,434,492	60,754,024	61,078,533	61,391,033	61,684,291	www.insee.fr
Germany	82,074,778	82,187,909	82,280,551	82,350,671	82,398,326	82,424,609	www.census.gov/cgi-bin/ipc/idbagg (for Germany)
Greece	10,882,607	10,917,457	10,949,953	10,987,559	11,023,532	11,040,650*	www.statistics.gr/eng_tables/S201_SPO_5_TS_91_03_2_Y_EN.pdf
Hungary					10,142,362	10,116,742#	portal.ksh.hu/portal/page?_pageid=38,119917&_dad=portal&_schema=PORTAL
Iceland	277,184	281,154	285,054	287,559	289,272	292,587	www.statice.is/?pageid=1178&src=/temp_en/mannfoldi/midarsmannfoldi.asp
Ireland	3,741,400	3,789,500	3,847,100	3,917,200	3,978,800	4,043,700	http://www.cso.ie/px/pxeirestat/database/eirestat/Population.asp
Italy	56,909,109	56,923,524	56,960,692	56,993,742	57,321,070	57,888,245	demo.istat.it/index_e.html
Latvia					2,331,480	2,319,203	data.csb.lv/EN/Database/annualstatistics/04.%20Population/04.%20Population.asp
Lithuania			3,486,998	3,475,586	3,462,553	3,445,857	epp.eurostat.ec.eu.int/extraction/evalight/EVAlight.jsp?A=1&language=en&root=/theme3/demo/dpop/ppavg (for Lithuania)
Luxembourg	433,600	439,000	439,000	444,050	448,300	451,600	http://www.statistiques.public.lu/stat/TableViewer/tableView.aspx?ReportId=1059
Malta	391,415~	391,415	394,641	397,242	399,867	399,867~	http://www.nso.gov.mt/statbase/data_table_options.aspx?id=19
Netherlands	15,760,225	15,863,950	15,987,075	16,105,285	16,192,572	16,258,032	statline.cbs.nl/StatWeb/start.asp?LA=en&DM=SL&IP=Search/Search
Norway	4,445,329	4,478,497	4,503,436	4,524,066	4,552,252	4,577,457	statbank.ssb.no/statistikkbanken/default_fr.asp?PLanguage=1
Poland	38,653,625	38,646,201	38,641,046	38,232,301	38,195,177	38,180,249	www.stat.gov.pl and National Institute of Hygiene, Poland
Portugal	10,195,014	10,262,877	10,335,559	10,407,465	10,474,685	10,529,255	www.ine.pt/prodserv/quadros/periodo.asp and Direcção-Geral da Saúde (Portugal)
Slovak Republic					5,379,161	5,380,053	www.census.gov/cgi-bin/ipc/idbagg (for Slovak Republic)
Slovenia	1,985,557	1,990,272	1,992,035	1,995,718	1,996,773	1,997,004	www.stat.si/eng/tema_demografsko_prebivalstvo.asp
Spain	39,802,827	40,049,708	40,476,723	40,964,244	41,663,702	42,345,342	www.ine.es/nebase/cgi/um?M=%2Ft20%2Fp251%2Fprov_2001%2F&O=pcaxis&N=&L=1 www.ine.es/nebase/cgi/um?M=%2Ft20%2Fp263%2Fpob_01%2F&O=pcaxis&N=&L=1
Sweden				8,940,788	8,946,957	9,011,392	www.ssd.scb.se/databaser/makro/MainTable.asp?yp=ianss&xu=C9233001&omradekod=BE&omradetext=Population&lang=2&lanqdb=2
Switzerland	7,164,444	7,204,055	7,261,210	7,313,853	7,364,148	7,415,102	www.bfs.admin.ch/bfs/portal/fr/index/infothek/lexikon/bienvenue_login/blank/zugang_lexikon.topic.1.html
United Kingdom	58,481,070	58,643,230	58,836,674	59,206,731	59,553,759	59,834,946	Office for National Statistics, www.statistics.gov.uk/
Year total	431,811,835	433,012,460	437,958,817	448,235,495	468,203,649	470,410,295	

* 1 Jan estimate; others for Greece are mid-year, (http://www.statistics.gr/eng_tables/S201_SPO_5_TS_91_04_4_Y_EN.pdf)

from National Centre for Epidemiology, Budapest, Hungary

~ 2000 figures used for 1999, and 2003 figures used for 2004

Table A3 Percentage age distribution of population, by country, 1999 – 2004 combined

Country	<1	1 - 4	5 – 9	10 - 14	15 - 19	20 – 24	25 - 44	45 – 64	65+
Austria	1.00	3.94	5.67	5.83	5.91	5.93	31.60	24.47	15.65
Belgium	1.10	4.48	5.86	6.04	5.92	6.19	29.20	24.28	16.94
Czech Republic	0.90	3.52	5.13	6.24	6.60	7.83	28.92	26.98	13.88
Denmark	1.22	5.03	6.46	5.94	5.33	5.91	29.21	26.03	14.87
Estonia	0.93	3.62	5.42	7.47	7.68	7.08	27.69	24.69	15.42
Finland	1.20	4.83	6.14	6.23	6.29	6.31	27.01	27.24	14.75
France	1.29	5.00	6.16	6.51	6.64	6.43	28.48	23.51	15.97
Germany	0.93	3.73	4.98	5.61	5.65	5.62	30.40	25.96	17.13
Greece	0.93	3.73	4.96	5.34	6.30	7.45	30.12	24.02	17.14
Hungary*	0.93	3.78	5.24	6.04	6.34	7.22	28.13	26.88	15.43
Iceland	1.47	5.95	7.79	7.79	7.37	7.64	29.40	20.95	11.64
Ireland	1.45	5.63	6.90	7.42	8.19	8.30	29.80	21.13	11.18
Italy	0.93	3.69	4.72	4.91	5.23	6.14	30.67	25.15	18.55
Latvia*	0.88	3.33	4.44	7.02	8.04	7.21	28.27	24.78	16.02
Lithuania~	0.90	4.02	6.07	7.66	7.90	6.95	29.31	22.61	14.57
Luxembourg~	1.20	5.00	6.42	6.16	5.71	5.78	31.74	23.87	14.12
Malta	1.03	4.45	6.37	7.13	7.27	7.58	27.51	25.96	12.69
Netherlands	1.26	4.99	6.19	6.13	5.88	6.03	31.02	24.85	13.65
Norway	1.28	5.32	6.82	6.55	5.97	6.13	29.37	23.52	15.04
Poland	0.95	4.07	6.06	7.30	8.48	8.34	28.27	24.02	12.52
Portugal	1.10	4.24	5.13	5.43	6.27	7.41	29.93	23.92	16.58
Slovak Republic*	0.95	3.97	5.74	7.17	8.02	8.58	29.89	24.18	11.49
Slovenia	0.88	3.66	4.97	5.87	6.72	7.50	30.35	25.60	14.45
Spain	0.98	3.74	4.75	5.24	6.22	7.76	32.02	22.46	16.81
Sweden#	1.10	4.18	5.50	6.93	6.17	5.80	27.08	26.02	17.21
Switzerland	1.02	4.23	5.69	5.94	5.80	5.86	30.64	25.26	15.56
United Kingdom	1.15	4.71	6.30	6.55	6.32	6.09	29.05	23.90	15.92
Overall	1.05	4.21	5.53	6.00	6.27	6.55	29.79	24.50	16.10

* 2003 and 2004 figures used

2002 – 2004 figures used

~ 2001 – 2004 figures used

Table A4 Confirmed, probable and confirmed, and laboratory-diagnosed, incidences (all per 100,000), by country 1999, 2003, 2004

Country	1999			2003			2004		
	Confirmed	Probable and confirmed	Laboratory-diagnosed	Confirmed	Probable and confirmed	Laboratory-diagnosed	Confirmed	Probable and confirmed	Laboratory-diagnosed
Austria	1.14	1.20	1.20	0.82	1.00	0.89	0.84	1.08	0.86
Belgium	2.90	2.90	2.90	2.18	2.20	2.20	1.49	1.51	1.51
Czech Republic	0.90	1.00	0.90	0.87	0.98	0.90	0.92	1.03	0.94
Denmark	3.33	3.50	3.33	1.91	1.95	1.91	1.81	1.85	1.81
Estonia	0.22	0.44	0.22	0.59	0.74	0.59	0.74	0.81	0.81
Finland	1.11	1.11	1.11	0.81	0.81	0.81	0.86	0.86	0.86
France	0.74	0.74	0.74	1.06	1.31	1.06	1.01	1.13	1.01
Germany*	0.49	0.49	0.49	0.93	0.94	0.93	0.72	0.73	0.72
Greece	1.77	1.94	1.19	1.08	1.19	1.08	0.65	0.65	0.65
Hungary	-	-	-	0.40	0.42	0.40	0.43	0.43	0.43
Iceland	7.58	7.58	7.58	2.07	2.77	2.77	2.73	3.42	3.42
Ireland	11.89	14.33	11.89	5.53	5.96	5.55	4.30	4.92	4.35
Italy	0.45	0.48	0.45	0.47	0.48	0.47	0.52	0.55	0.54
Latvia	-	-	-	0.64	1.03	0.69	0.78	1.03	0.99
Lithuania	-	-	-	0.87	1.27	0.87	1.54	2.67	1.54
Luxembourg	1.53	5.68	4.15	0.25	0.70	0.22	0.25	0.25	0.00
Malta	4.34	5.88	4.34	4.00	4.25	4.00	3.00	3.25	3.25
Netherlands	3.65	3.65	3.65	2.19	2.19	2.19	1.71	1.75	1.71
Norway	1.73	1.80	1.73	1.08	1.12	1.12	0.70	0.74	0.74
Poland	0.17	0.17	0.17	0.15	0.15	0.15	0.30	0.31	0.30
Portugal	-	-	-	1.34	1.93	1.34	1.18	1.73	1.18
Slovak Republic	-	-	-	0.91	0.91	0.91	0.59	0.59	0.59
Slovenia	0.30	0.30	0.30	0.80	0.80	0.80	0.45	0.45	0.45
Spain	2.38	3.52	2.38	1.08	1.19	1.18	1.64	2.11	1.64
Sweden	-	-	-	0.61	0.63	0.61	0.62	0.65	0.62
Switzerland	2.09	2.36	2.09	1.02	1.19	1.02	1.07	1.16	1.07
United Kingdom	4.72	5.39	5.24	2.85	3.10	3.03	2.31	2.55	2.46

* Data for 1999 from Institute for Hygiene and Microbiology Reference Laboratory; other years from Robert Koch Institute

Table A5 Number of cases of confirmed and probable laboratory-diagnosed (% culture-diagnosed) invasive meningococcal disease, by country, 1999 – 2004

Country	1999	2000	2001	2002	2003	2004
Austria	97 (82%)	83 (70%)	106 (86%)	81 (74%)	73 (78%)	70 (77%)
Belgium	297 (100%)	267 (100%)	380 (100%)	262 (100%)	228 (100%)	157 (100%)
Czech Republic	93 (96%)	61 (93%)	93 (97%)	113 (74%)	92 (71%)	96 (97%)
Denmark	177 (85%)	151 (80%)	161 (83%)	98 (89%)	103 (82%)	98 (81%)
Estonia	3 (67%)	9 (100%)	20 (95%)	8 (100%)	8 (88%)	11 (91%)
Finland	57 (100%)	48 (100%)	49 (98%)	49 (98%)	42 (100%)	45 (91%)
France	448 (100%)	489 (95%)	559 (94%)	648 (94%)	650 (99%)	625 (85%)
Germany*	402 (100%)	452 (100%)	770 (69%)	730 (74%)	768 (73%)	596 (74%)
Greece	130 (55%)	174 (36%)	185 (31%)	196 (26%)	119 (33%)	72 (54%)
Hungary					41 (83%)	43 (93%)
Iceland	21 (100%)	18 (89%)	19 (89%)	15 (87%)	8 (100%)	10 (100%)
Ireland	445 (42%)	411 (41%)	297 (34%)	225 (36%)	221 (34%)	176 (40%)
Italy	254 (63%)	243 (67%)	201 (67%)	214 (72%)	271 (77%)	314 (67%)
Latvia					16 (100%)	23 (100%)
Lithuania			35 (49%)	29 (66%)	30 (57%)	53 (60%)
Luxembourg	18	1	1	1	1	0
Malta	17 (71%)	20 (80%)	13 (92%)	14 (71%)	16 (94%)	13 (92%)
Netherlands	576 (98%)	542 (100%)	721 (100%)	616 (100%)	354 (100%)	278 (95%)
Norway	77 (95%)	85 (87%)	77 (87%)	51 (92%)	51 (84%)	34 (85%)
Poland	67 (100%)	43 (100%)	37 (100%)	35 (100%)	57 (93%)	116 (98%)
Portugal		59 (100%)	106 (100%)	185 (79%)	140 (66%)	124 (91%)
Slovak Republic					49 (86%)	32 (78%)
Slovenia	6 (100%)	8 (100%)	10 (100%)	8 (100%)	16 (100%)	9 (100%)
Spain[#]	947 (0%)	971 (0%)	643 (0%)	834 (0%)	493 (95%)	696 (100%)
Sweden				46 (93%)	55 (80%)	56 (89%)
Switzerland	150 (99%)	149 (97%)	147 (98%)	91 (92%)	75 (97%)	79 (82%)
United Kingdom	3064 (61%)	2993 (56%)	2570 (52%)	1948 (54%)	1807 (54%)	1474 (53%)
Total	7346 (64%)	7277 (61%)	7200 (64%)	6497 (62%)	5784 (74%)	5300 (75%)

* Data for 1999 and 2000 from Institute for Hygiene and Microbiology Reference Laboratory; other years from Robert Koch Institute

Data for 2003 from Centro Nacional de Microbiologia; all other years from Centro Nacional de Epidemiologia

Table A6 Incidence (per 100,000) of confirmed and probable culture-diagnosed cases of invasive meningococcal disease, by country, 1999 - 2004

Country	1999	2000	2001	2002	2003	2004
Austria	0.99	0.71	1.12	0.74	0.70	0.66
Belgium	2.90	2.60	3.69	2.54	2.20	1.51
Czech Republic	0.87	0.56	0.88	0.82	0.64	0.91
Denmark	2.84	2.27	2.50	1.62	1.56	1.46
Estonia	0.15	0.66	1.39	0.59	0.52	0.74
Finland	1.11	0.93	0.93	0.92	0.81	0.79
France	0.74	0.77	0.86	1.00	1.05	0.87
Germany*	0.49	0.55	0.64	0.65	0.68	0.54
Greece	0.65	0.57	0.53	0.46	0.35	0.35
Hungary					0.34	0.40
Iceland	7.58	5.69	5.96	4.52	2.77	3.42
Ireland	5.05	4.46	2.60	2.09	1.88	1.76
Italy	0.28	0.29	0.24	0.27	0.36	0.36
Latvia					0.69	0.99
Lithuania			0.49	0.58	0.49	0.93
Malta	3.07	4.09	3.04	2.52	3.75	3.00
Netherlands	3.60	3.40	4.50	3.82	2.19	1.62
Norway	1.64	1.65	1.49	1.04	0.94	0.63
Poland	0.17	0.11	0.10	0.09	0.14	0.30
Portugal		0.57	1.03	1.41	0.89	1.07
Slovak Republic					0.78	0.46
Slovenia	0.30	0.40	0.50	0.40	0.80	0.45
Spain [#]	1.51	1.73	0.97	1.37	1.57	1.64
Sweden				0.48	0.49	0.55
Switzerland	2.08	2.00	1.98	1.15	0.99	0.88
United Kingdom	3.17	2.86	2.29	1.77	1.64	1.31
Total~	1.43	1.31	1.30	1.09	0.98	0.85

* Data for 1999 and 2000 from Institute for Hygiene and Microbiology Reference Laboratory; other years from Robert Koch Institute

Data for 2004 from Centro Nacional de Epidemiología; all other years from Centro Nacional de Microbiología

~ Calculated using data from countries submitting consistent data 1999 - 2004 (see Table A1)

Table A7 Incidence (per 100,000) of laboratory-diagnosed confirmed and probable cases of invasive meningococcal disease, by country, 1999 - 2004

Country	% PCR* (years done)	1999	2000	2001	2002	2003	2004
Austria	23.53% (1999-2004)	1.20	1.02	1.30	0.99	0.89	0.86
Belgium	1.00% (2000-2004)	2.90	2.60	3.69	2.54	2.20	1.51
Czech Republic	23.72% (1999-2004)	0.90	0.59	0.91	1.11	0.90	0.94
Denmark		3.33	2.83	3.01	1.82	1.91	1.81
Estonia		0.22	0.66	1.46	0.59	0.59	0.81
Finland	0.69% (2004)	1.11	0.93	0.95	0.94	0.81	0.86
France	3.60% (2002-2004)	0.74	0.81	0.92	1.06	1.06	1.01
Germany~	7.40% (2001-2004)	0.49	0.55	0.94	0.89	0.93	0.72
Greece	70.43% (1999-2004)	1.19	1.59	1.69	1.78	1.08	0.65
Hungary	13.10% (2003-2004)					0.40	0.43
Iceland	8.79% (2001-2004)	7.58	6.40	6.67	5.22	2.77	3.42
Ireland	63.77% (1999-2004)	11.89	10.85	7.72	5.74	5.55	4.35
Italy		0.45	0.43	0.35	0.38	0.47	0.54
Latvia	2.56% (2004)					0.69	0.99
Lithuania				1.00	0.83	0.87	1.54
Luxembourg		4.15	0.23	0.23	0.23	0.22	0.00
Malta	2.15% (2001-2002)	4.34	5.11	3.29	3.52	4.00	3.25
Netherlands	0.75% (2003-2004)	3.65	3.42	4.51	3.82	2.19	1.71
Norway	9.60% (1999-2004)	1.73	1.90	1.71	1.13	1.12	0.74
Poland	4.79% (2002-2004)	0.17	0.11	0.10	0.09	0.15	0.30
Portugal	8.63% (2002-2004)		0.57	1.03	1.78	1.34	1.18
Slovak Republic						0.91	0.59
Slovenia		0.30	0.40	0.50	0.40	0.80	0.45
Spain [#]		2.38	2.42	1.59	2.04	1.18	1.64
Sweden	15.29% (2002-2004)				0.51	0.61	0.62
Switzerland	3.62% (1999-2004)	2.09	2.07	2.02	1.24	1.02	1.07
United Kingdom	64.56% (1999-2004)	5.24	5.10	4.37	3.29	3.03	2.46
Total**		2.00	1.93	1.87	1.55	1.38	1.21

* of all cases used to calculate laboratory-diagnosed incidence

** Calculated using data from countries submitting consistent data 1999 - 2004 (see Table A1)

~ Data for 1999 and 2000 from Institute for Hygiene and Microbiology Reference Laboratory; other years from Robert Koch Institute

Data for 2004 from Centro Nacional de Epidemiología; all other years from Centro Nacional de Microbiología

Table A8 Age distribution (number and % distribution) of cases of confirmed and probable laboratory-diagnosed meningococcal disease, all countries, 1999 - 2004

Age Group	1999	2000	2001	2002	2003	2004
<i>Number of cases</i>						
<1 year	978	981	960	810	761	706
1 - 4 years	1580	1542	1400	1243	1132	926
5 - 9 years	637	586	553	453	357	299
10 - 14 years	498	399	444	312	314	209
15 - 19 years	878	725	784	602	534	510
20 - 24 years	289	341	293	244	229	182
25 - 44 years	430	511	518	409	350	312
45 - 64 years	355	427	399	322	296	298
65+ years	260	268	272	267	202	225
Not known	74	14	22	10	16	10
<i>% distribution</i>						
<1 year	16.36%	16.93%	17.01%	17.34%	18.16%	19.20%
1 - 4 years	26.43%	26.61%	24.80%	26.61%	27.01%	25.18%
5 - 9 years	10.65%	10.11%	9.80%	9.70%	8.52%	8.13%
10 - 14 years	8.33%	6.89%	7.87%	6.68%	7.49%	5.68%
15 - 19 years	14.68%	12.51%	13.89%	12.89%	12.74%	13.87%
20 - 24 years	4.83%	5.89%	5.19%	5.22%	5.46%	4.95%
25 - 44 years	7.19%	8.82%	9.18%	8.75%	8.35%	8.49%
45 - 64 years	5.94%	7.37%	7.07%	6.89%	7.06%	8.10%
65+ years	4.35%	4.63%	4.82%	5.71%	4.82%	6.12%
Not known	1.24%	0.24%	0.39%	0.21%	0.38%	0.27%

Calculated using data from countries submitting consistent data 1999 - 2004 (see Table A1)

Table A9 Age-specific incidence (per 100,000) of confirmed and probable laboratory-diagnosed meningococcal disease, by country, 2003

Country	<1 year	1 - 4 years	5 – 9 years	10 - 14 years	15 - 19 years	20 - 24 years	25 - 44 years	45 - 64 years	65+ years
Austria	7.77	5.83	1.11	2.92	2.52	0.81	0.31	0.24	0.08
Belgium	26.83	14.34	4.22	3.93	5.43	1.24	0.64	0.55	0.45
Czech Republic	17.08	3.59	0.64	1.28	4.37	0.41	0.50	0.14	0.07
Denmark	15.76	11.24	3.44	4.48	5.86	1.33	0.19	0.49	0.62
Estonia	0.00	2.03	1.54	0.00	1.87	1.02	0.27	0.30	0.46
Finland	3.41	1.42	0.64	0.30	2.49	1.52	0.43	0.48	0.77
France	10.86	4.43	1.48	1.21	2.87	1.49	0.31	0.29	0.50
Germany	14.14	5.97	1.59	1.43	3.80	1.10	0.21	0.22	0.18
Greece	16.74	7.38	6.05	2.64	1.55	0.50	0.15	0.15	0.10
Hungary	15.79	2.09	0.37	0.32	0.62	0.53	0.14	0.04	0.06
Iceland	0.00	23.72	4.59	0.00	0.00	0.00	1.19	0.00	5.89
Ireland	100.66	32.13	5.97	4.63	8.47	2.08	1.00	1.29	0.68
Italy	5.44	2.60	0.79	0.67	1.11	0.82	0.25	0.20	0.11
Latvia	9.98	7.84	0.00	1.77	0.00	0.00	0.45	0.17	0.27
Lithuania	43.61	7.29	0.00	0.38	0.36	0.41	0.30	0.13	0.00
Malta	49.66	12.09	8.23	10.71	7.04	6.62	1.82	0.94	0.00
Netherlands	31.62	11.83	3.76	2.79	2.92	1.64	0.65	0.68	1.08
Norway	10.79	3.80	1.94	1.62	4.04	1.46	0.15	0.46	0.45
Poland	3.43	1.14	0.09	0.30	0.19	0.03	0.03	0.03	0.04
Portugal	31.09	11.92	3.79	0.53	0.97	0.27	0.22	0.20	0.23
Slovak Republic	21.77	6.92	0.63	0.26	2.30	0.65	0.25	0.08	0.32
Slovenia	11.51	5.57	0.00	0.91	4.63	0.67	0.17	0.19	0.00
Spain	10.77	5.64	2.33	1.76	2.28	0.55	0.34	0.40	0.54
Sweden	7.05	0.80	0.85	1.76	1.45	0.77	0.33	0.26	0.26
Switzerland	12.58	2.70	2.21	0.91	3.04	1.60	0.36	0.53	0.61
United Kingdom	60.05	20.83	3.51	2.75	4.77	2.02	0.78	0.86	0.81

Table A10 Age-specific incidence (per 100,000) of confirmed and probable laboratory-diagnosed meningococcal disease, by country, 2004

Country	<1 year	1 - 4 years	5 – 9 years	10 - 14 years	15 - 19 years	20 - 24 years	25 - 44 years	45 - 64 years	65+ years
Austria	13.17	4.94	1.60	0.83	3.77	0.60	0.24	0.24	0.15
Belgium	22.79	8.93	3.05	0.63	3.41	0.62	0.57	0.50	0.73
Czech Republic	16.01	4.97	2.12	0.80	2.56	1.35	0.33	0.32	0.14
Denmark	16.95	6.08	2.31	4.09	7.02	0.68	0.32	0.63	1.48
Estonia	0.00	3.97	0.00	0.00	0.00	0.99	0.27	1.49	0.91
Finland	16.05	2.23	0.00	0.30	1.57	0.60	0.36	0.89	0.61
France	11.54	3.14	1.60	0.82	3.25	1.46	0.31	0.34	0.50
Germany	14.02	3.88	1.30	0.77	2.80	0.93	0.17	0.20	0.22
Greece	13.76	4.91	2.26	0.88	1.24	0.50	0.12	0.15	0.05
Hungary	15.06	3.39	0.19	0.00	0.78	0.28	0.07	0.18	0.06
Iceland	23.45	23.90	4.65	0.00	0.00	0.00	0.00	3.07	5.83
Ireland	68.18	32.24	5.46	2.88	5.98	3.25	0.24	0.34	0.44
Italy	5.37	3.49	0.94	1.05	1.32	0.55	0.30	0.23	0.09
Latvia	9.54	7.64	1.00	1.27	2.14	1.17	0.15	0.52	0.53
Lithuania	62.48	15.33	0.52	1.56	0.72	0.40	0.30	0.38	0.00
Malta	49.66	12.09	4.11	10.71	7.04	0.00	0.91	1.88	0.00
Netherlands	25.40	9.39	2.74	1.49	3.29	0.52	0.43	0.55	1.20
Norway	19.43	0.85	0.00	0.32	3.57	1.09	0.15	0.27	0.30
Poland	8.22	1.99	0.38	0.27	0.69	0.09	0.06	0.04	0.06
Portugal	38.41	11.03	2.42	0.90	0.67	0.14	0.12	0.12	0.17
Slovak Republic	21.41	3.32	0.66	0.52	1.40	0.22	0.12	0.08	0.00
Slovenia	11.51	4.18	0.00	0.94	2.36	0.00	0.00	0.00	0.00
Spain	29.69	9.40	3.13	1.66	3.13	1.35	0.53	0.55	0.97
Sweden	5.94	2.08	0.42	0.49	2.44	1.15	0.21	0.30	0.32
Switzerland	16.47	2.39	1.74	1.60	4.61	1.13	0.27	0.57	0.34
United Kingdom	49.81	16.28	2.77	1.86	3.70	1.37	0.69	0.74	0.92

Table A11 Serogroup distribution of cases of confirmed and probable laboratory-diagnosed meningococcal disease, by country, 2003

Country	Serogroup B	Serogroup C	Serogroup W135	Serogroup Y	Other serogroups	Non-groupable	Not known	Serogroup C vaccination (year of introduction)
Austria	52	14	1	1	1	2	2	
Belgium	166	47	3	2	1	0	9	Yes (2002)
Czech Republic	39	40	3	2	1	0	7	
Denmark	59	20	2	4	0	0	18	
Estonia	6	1	0	0	0	0	1	
Finland	28	5	0	8	0	1	0	
France	209	111	16	13	1	0	300	
Germany	365	165	12	23	1	0	2	
Greece	53	2	5	1	17	23	18	
Hungary	35	4	0	1	0	0	1	
Iceland	5	2	1	0	0	0	0	Yes (2002)
Ireland	206	5	3	2	0	4	1	Yes (2000)
Italy	89	67	3	0	1	0	111	
Latvia	3	0	0	0	0	0	13	
Lithuania	10	3	0	0	0	0	17	
Luxembourg	1	0	0	0	0	0	0	
Malta	5	1	0	0	0	0	10	
Netherlands	297	44	6	5	2	0	0	Yes (2002)
Norway	36	9	2	1	0	2	1	
Poland	33	21	1	0	0	0	2	
Portugal	67	50	6	0	1	2	14	
Slovak Republic	28	11	1	0	1	0	8	
Slovenia	6	3	3	2	0	2	0	
Spain	357	93	14	21	1	7	0	Yes (2000)
Sweden	29	13	2	2	0	0	9	
Switzerland	37	23	4	5	0	2	4	
United Kingdom	1523	106	46	22	7	7	96	Yes (1999)
Total	3744	860	134	115	35	52	644	

Table A12 Incidence (per 100,000) of confirmed and probable laboratory-diagnosed meningococcal disease, by serogroup and country, 2003

Country	Serogroup B	Serogroup C	Serogroup W135	Serogroup Y	Other serogroups	Non-groupable	Not known	Serogroup C vaccination (year of introduction)
Austria	0.64	0.17	0.01	0.01	0.01	0.02	0.02	
Belgium	1.60	0.45	0.03	0.02	0.01	0.00	0.09	Yes (2002)
Czech Republic	0.38	0.39	0.03	0.02	0.01	0.00	0.07	
Denmark	1.10	0.37	0.04	0.07	0.00	0.00	0.33	
Estonia	0.44	0.07	0.00	0.00	0.00	0.00	0.07	
Finland	0.54	0.10	0.00	0.15	0.00	0.02	0.00	
France	0.34	0.18	0.03	0.02	0.00	0.00	0.49	
Germany	0.44	0.20	0.01	0.03	0.00	0.00	0.00	
Greece	0.48	0.02	0.05	0.01	0.15	0.21	0.16	
Hungary	0.35	0.04	0.00	0.01	0.00	0.00	0.01	
Iceland	1.73	0.69	0.35	0.00	0.00	0.00	0.00	Yes (2002)
Ireland	5.18	0.13	0.08	0.05	0.00	0.10	0.03	Yes (2000)
Italy	0.16	0.12	0.01	0.00	0.00	0.00	0.19	
Latvia	0.13	0.00	0.00	0.00	0.00	0.00	0.56	
Lithuania	0.29	0.09	0.00	0.00	0.00	0.00	0.49	
Luxembourg	0.22	0.00	0.00	0.00	0.00	0.00	0.00	
Malta	1.25	0.25	0.00	0.00	0.00	0.00	2.50	
Netherlands	1.83	0.27	0.04	0.03	0.01	0.00	0.00	Yes (2002)
Norway	0.79	0.20	0.04	0.02	0.00	0.04	0.02	
Poland	0.09	0.05	0.00	0.00	0.00	0.00	0.01	
Portugal	0.64	0.48	0.06	0.00	0.01	0.02	0.13	
Slovak Republic	0.52	0.20	0.02	0.00	0.02	0.00	0.15	
Slovenia	0.30	0.15	0.15	0.10	0.00	0.10	0.00	
Spain	0.86	0.22	0.03	0.05	0.00	0.02	0.00	Yes (2000)
Sweden	0.32	0.15	0.02	0.02	0.00	0.00	0.10	
Switzerland	0.50	0.31	0.05	0.07	0.00	0.03	0.05	
United Kingdom	2.56	0.18	0.08	0.04	0.01	0.01	0.16	Yes (1999)
Total	0.80	0.18	0.03	0.02	0.01	0.01	0.14	

Table A13 Serogroup distribution of cases of confirmed and probable laboratory-diagnosed meningococcal disease, by country, 2004

Country	Serogroup B	Serogroup C	Serogroup W135	Serogroup Y	Other serogroups	Non-groupable	Not known	Serogroup C vaccination (year of introduction)
Austria	43	18	3	2	0	0	4	
Belgium	124	21	5	3	1	1	2	Yes (2002)
Czech Republic	54	32	2	2	1	0	5	
Denmark	58	14	2	3	1	0	20	
Estonia	3	2	0	0	1	0	5	
Finland	30	5	2	4	0	0	4	
France	348	188	25	17	8	2	37	
Germany	306	122	4	14	1	0	0	
Greece	43	0	0	0	3	1	25	
Hungary	37	3	0	0	0	0	3	
Iceland	6	3	1	0	0	0	0	Yes (2002)
Ireland	163	5	1	2	0	1	4	Yes (2000)
Italy	73	99	3	6	0	0	133	
Latvia	9	0	0	1	0	0	13	
Lithuania	32	5	0	0	0	0	16	
Malta	6	0	0	0	1	0	6	
Netherlands	238	17	4	6	1	0	12	Yes (2002)
Norway	25	4	1	1	0	0	3	
Poland	72	41	0	2	0	1	0	
Portugal	92	15	4	4	2	0	7	
Slovak Republic	18	6	0	0	1	0	7	
Slovenia	7	0	2	0	0	0	0	
Spain	474	146	19	3	2	45	7	Yes (2000)
Sweden	28	11	6	6	0	1	4	
Switzerland	36	18	2	2	0	1	20	
United Kingdom	1253	65	39	35	7	2	73	Yes (1999)
Total	3578	840	125	113	30	55	410	

Table A14 Incidence (per 100,000) of confirmed and probable laboratory-diagnosed meningococcal disease, by serogroup and country, 2004

Country	Serogroup B	Serogroup C	Serogroup W135	Serogroup Y	Other serogroups	Non-groupable	Not known	Serogroup C vaccination (year of introduction)
Austria	0.53	0.22	0.04	0.02	0.00	0.00	0.05	
Belgium	1.19	0.20	0.05	0.03	0.01	0.01	0.02	Yes (2002)
Czech Republic	0.53	0.31	0.02	0.02	0.01	0.00	0.05	
Denmark	1.07	0.26	0.04	0.06	0.02	0.00	0.37	
Estonia	0.22	0.15	0.00	0.00	0.07	0.00	0.37	
Finland	0.58	0.10	0.04	0.08	0.00	0.00	0.08	
France	0.56	0.30	0.04	0.03	0.01	0.00	0.06	
Germany	0.37	0.15	0.00	0.02	0.00	0.00	0.00	
Greece	0.39	0.00	0.00	0.00	0.03	0.01	0.23	
Hungary	0.37	0.03	0.00	0.00	0.00	0.00	0.03	
Iceland	2.05	1.03	0.34	0.00	0.00	0.00	0.00	Yes (2002)
Ireland	4.03	0.12	0.02	0.05	0.00	0.02	0.10	Yes (2000)
Italy	0.13	0.17	0.01	0.01	0.00	0.00	0.23	
Latvia	0.39	0.00	0.00	0.04	0.00	0.00	0.56	
Lithuania	0.93	0.15	0.00	0.00	0.00	0.00	0.46	
Malta	1.50	0.00	0.00	0.00	0.25	0.00	1.50	
Netherlands	1.46	0.10	0.02	0.04	0.01	0.00	0.07	Yes (2002)
Norway	0.55	0.09	0.02	0.02	0.00	0.00	0.07	
Poland	0.19	0.11	0.00	0.01	0.00	0.00	0.00	
Portugal	0.87	0.14	0.04	0.04	0.02	0.00	0.07	
Slovak Republic	0.33	0.11	0.00	0.00	0.02	0.00	0.13	
Slovenia	0.35	0.00	0.10	0.00	0.00	0.00	0.00	
Spain	1.12	0.34	0.04	0.01	0.00	0.11	0.02	Yes (2000)
Sweden	0.31	0.12	0.07	0.07	0.00	0.01	0.04	
Switzerland	0.49	0.24	0.03	0.03	0.00	0.01	0.27	
United Kingdom	2.09	0.11	0.07	0.06	0.01	0.00	0.12	Yes (1999)
Total	0.76	0.18	0.03	0.02	0.01	0.01	0.09	

Table A15 Age distribution of cases of confirmed and probable laboratory-diagnosed serogroup B meningococcal disease, all countries, 1999 – 2004

Age group	1999	2000	2001	2002	2003	2004
Number of cases						
<1 year	692	770	741	632	622	587
1 - 4 years	992	1006	992	907	858	729
5 - 9 years	375	331	341	296	240	198
10 – 14 years	255	189	262	196	202	131
15 – 19 years	446	413	442	340	335	332
20 – 24 years	155	175	151	124	119	127
25 – 44 years	214	250	255	206	200	165
45 – 64 years	179	234	192	174	176	184
65+ years	125	112	101	106	90	120
Not known	53	10	7	7	8	9
Total	3486	3490	3484	2988	2850	2582
% distribution						
<1 year	19.85%	22.06%	21.27%	21.15%	21.82%	22.73%
1 - 4 years	28.46%	28.83%	28.47%	30.35%	30.11%	28.23%
5 - 9 years	10.76%	9.48%	9.79%	9.91%	8.42%	7.67%
10 – 14 years	7.31%	5.42%	7.52%	6.56%	7.09%	5.07%
15 – 19 years	12.79%	11.83%	12.69%	11.38%	11.75%	12.86%
20 – 24 years	4.45%	5.01%	4.33%	4.15%	4.18%	4.92%
25 – 44 years	6.14%	7.16%	7.32%	6.89%	7.02%	6.39%
45 – 64 years	5.13%	6.70%	5.51%	5.82%	6.18%	7.13%
65+ years	3.59%	3.21%	2.90%	3.55%	3.16%	4.65%
Not known	1.52%	0.29%	0.20%	0.23%	0.28%	0.35%

Calculated using data from countries submitting consistent data 1999 - 2004 (see Table A1)

Table A16 Age distribution of cases of confirmed and probable laboratory-diagnosed serogroup C meningococcal disease, all countries, 1999 – 2004

Age group	1999	2000	2001	2002	2003	2004
Number of cases						
<1 year	174	89	92	77	40	50
1 - 4 years	413	346	222	179	99	100
5 - 9 years	181	164	103	82	41	48
10 – 14 years	171	136	98	73	44	42
15 – 19 years	338	214	236	175	82	99
20 – 24 years	93	127	101	84	47	29
25 – 44 years	125	169	166	132	69	74
45 – 64 years	122	114	144	94	56	53
65+ years	74	96	85	82	41	36
Not known	20	3	9	1	2	1
Total	1711	1458	1256	979	521	532
% distribution						
<1 year	10.17%	6.10%	7.32%	7.87%	7.68%	9.40%
1 - 4 years	24.14%	23.73%	17.68%	18.28%	19.00%	18.80%
5 - 9 years	10.58%	11.25%	8.20%	8.38%	7.87%	9.02%
10 – 14 years	9.99%	9.33%	7.80%	7.46%	8.45%	7.89%
15 – 19 years	19.75%	14.68%	18.79%	17.88%	15.74%	18.61%
20 – 24 years	5.44%	8.71%	8.04%	8.58%	9.02%	5.45%
25 – 44 years	7.31%	11.59%	13.22%	13.48%	13.24%	13.91%
45 – 64 years	7.13%	7.82%	11.46%	9.60%	10.75%	9.96%
65+ years	4.32%	6.58%	6.77%	8.38%	7.87%	6.77%
Not known	1.17%	0.21%	0.72%	0.10%	0.38%	0.19%

Calculated using data from countries submitting consistent data 1999 - 2004 (see Table A1)

Table A17 Percentage distribution of confirmed and probable laboratory-diagnosed cases due to serogroup C, by country (total serogroup cases), 1999 - 2004

	1999	2000	2001	2002	2003	2004
No Serogroup C	Estonia (3)	Estonia (9)	Luxembourg (1)	Estonia (8)	Luxembourg (1)	Greece (72)
	Slovenia (6)					Luxembourg (0)
						Malta (13)
						Slovenia (9)
<10%		Malta (20)	Greece (185)	Greece (196)	Greece (119)	Ireland (176)
			Malta (13)	Ireland (225)	Ireland (221)	Netherlands (278)
				United Kingdom (1948)	Malta (16)	United Kingdom (1474)
					United Kingdom (1807)	
10 - 19%	Austria (97)	Austria (83)	Denmark (161)	Denmark (98)	Austria (73)	Belgium (157)
	Denmark (177)	Czech Republic (61)	Estonia (20)	Finland (49)	Denmark (103)	Denmark (98)
	Finland (57)	Denmark (151)	Finland (49)	Malta (14)	Estonia (8)	Estonia (11)
	Italy (254)	Greece (174)	Ireland (297)	Slovenia (8)	Finland (42)	Finland (45)
	Malta (17)	Italy (243)	Italy (201)		France (650)	Norway (34)
	Netherlands (576)	Norway (85)	Norway (77)		Netherlands (354)	
	Norway (77)	Poland (43)	Poland (37)		Norway (51)	
	Poland (67)	Slovenia (8)	Slovenia (10)		Slovenia (16)	
			United Kingdom (2570)			
20 - 29%	Belgium (297)	Finland (48)	Germany (530)	Austria (81)	Belgium (228)	Austria (70)
	France (448)	France (489)		Italy (214)	Germany (567)	Germany (447)
	Germany (402)	Germany (452)		Norway (51)	Iceland (8)	Switzerland (79)
	Greece (130)	Netherlands (542)			Italy (271)	
	Luxembourg (18)	United Kingdom (2993)				
30 - 39%	Ireland (445)	Belgium (267)	Austria (106)	Belgium (262)	Poland (57)	Czech Republic (96)
	Switzerland (150)	Ireland (411)	Czech Republic (93)	Czech Republic (113)	Switzerland (75)	France (625)
	United Kingdom (3064)		France (559)	France (648)		Iceland (10)
			Netherlands (721)	Germany (580)		Italy (314)
				Netherlands (616)		Poland (116)
			Poland (35)			
>=40%	Czech Republic (93)	Iceland (18)	Belgium (380)	Iceland (15)	Czech Republic (92)	
	Iceland (21)	Luxembourg (1)	Iceland (19)	Luxembourg (1)		
		Switzerland (149)	Switzerland (147)	Switzerland (91)		

Calculated using data from countries submitting consistent data 1999 - 2004 (see Table A1)

Table A18 Dominant serotype of confirmed and probable laboratory-diagnosed serogroup C invasive meningococcal disease (number of serotyped C cases), by country, 1999 - 2004

Serotype	1999	2000	2001	2002	2003	2004
P2.2a	Czech Republic (26)	Austria (10)	Austria (34)	Austria (17)	Belgium (46)	Belgium (20)
	Denmark (21)	Belgium (85)	Belgium (178)	Belgium (89)	Czech Republic (23)	Czech Republic (25)
	Greece (17)	Czech Republic (10)	Czech Republic (23)	Czech Republic (28)	France (109)	France (127)
	Ireland (42)	Denmark (16)	Denmark (24)	Denmark (16)	Greece (2)	Ireland (1)
	Italy (16)	Greece (9)	France (126)	Finland (6)	Ireland (2)	Netherlands (17)
	Malta (1)	Ireland (54)	Greece (8)	France (172)	Malta (1)	Norway (1)
	Netherlands (81)	Italy (24)	Ireland (6)	Greece (6)	Netherlands (44)	Switzerland (18)
	Norway (10)	Netherlands (106)	Italy (15)	Ireland (4)	Norway (9)	United Kingdom (33)
	United Kingdom (713)	Norway (12)	Netherlands (277)	Netherlands (222)	Switzerland (23)	
		Slovenia (1)	Norway (13)	Slovenia (1)	United Kingdom (65)	
		United Kingdom (514)	Slovenia (1)	Switzerland (39)	Austria (12)	
		United Kingdom (220)	United Kingdom (128)			
P2.2b	Austria (14)	Malta (1)	Switzerland (69)	Italy (32)	Italy (55)	Italy (83)
	Belgium (77)	Switzerland (83)				
	France (100)					
	Switzerland (57)					
P3.15				Norway (3)	Denmark (19)	Denmark (14)
P3.22	Poland (8)					
P3.4			Poland (4)	Norway (3)		
NT	Finland (9)	Finland (10)	Finland (9)	Greece (6)	Finland (5)	Austria (15)
	Poland (8)	Poland (7)	Malta (1)	Norway (3)	Poland (21)	Finland (5)
			Norway (13)	Poland (11)	Slovenia (3)	Poland (40)

Table A19 Dominant serotype of confirmed and probable laboratory-diagnosed serogroup B invasive meningococcal disease (number of serotyped B cases), by country, 1999 – 2004

Serotype	1999	2000	2001	2002	2003	2004
P3.14	Italy (60)					
P3.15	Austria (60)	Austria (45)	Denmark (92)	Denmark (65)	Czech Republic (20)	Austria (32)
	Denmark (126)	Denmark (98)	Italy (46)		Denmark (57)	Denmark (56)
	Norway (57)	Norway (49)	Norway (32)		Italy (66)	Italy (48)
		Slovenia (4)	Slovenia (8)			Norway (19)
P3.22			Poland (29)		Slovenia (6)	
P3.4	Belgium (198)	Belgium (165)	Belgium (169)	Belgium (161)	Belgium (164)	Belgium (122)
	Finland (33)	Finland (29)	Finland (34)	Czech Republic (37)	Finland (28)	Czech Republic (40)
	Ireland (86)	Greece (20)	Greece (35)	Greece (37)	Greece (28)	Finland (29)
	Malta (6)	Ireland (86)	Ireland (55)	Italy (47)	Malta (3)	Greece (29)
	Netherlands (466)	Italy (61)	Malta (9)	Malta (6)	Netherlands (293)	Ireland (45)
	United Kingdom (1020)	Malta (13)	Netherlands (417)	Netherlands (371)	Norway (31)	Netherlands (232)
		Netherlands (413)		Norway (24)		Norway (19)
						Switzerland (36)
NT	Czech Republic (36)	Austria (45)	Austria (46)	Austria (39)	Austria (37)	France (233)
	France (302)	Czech Republic (34)	Czech Republic (34)	Finland (35)	Finland (28)	Ireland (45)
	Greece (30)	Poland (33)	France (194)	France (224)	France (205)	Malta (4)
	Poland (55)	Switzerland (48)	Slovenia (8)	Ireland (51)	Ireland (49)	Poland (71)
	Slovenia (6)	United Kingdom (1018)	Switzerland (52)	Poland (23)	Poland (31)	Slovenia (5)
	Switzerland (59)		United Kingdom (964)	Slovenia (5)	Slovenia (6)	United Kingdom (631)
				Switzerland (34)	Switzerland (37)	
				United Kingdom (796)	United Kingdom (779)	

Table A20 Number of cases of phenotype B:P2.2a or B:P2.2b in sentinel countries involved in the rapid surveillance project by year and month, 1999-2004

Year	Month	Countries without routine MCC vaccination						Countries with routine MCC vaccination			
		Austria	Czech Republic	Denmark	France	Greece	Italy	Ireland	Netherlands	Spain	United Kingdom
1999	January					1				1	6
	February	1	1	1		1				2	2
	March				1	2			1	1	2
	April				1					1	3
	May		1						1		1
	June				1				1		1
	July				1					2	1
	August	1									
	September										
	October				1				1		1
	November					1				1	2
	December		1								2
2000	January		1			1					10
	February			1		1				1	2
	March	1				2				2	1
	April									1	2
	May					2				2	
	June									1	
	July						1		1	1	1
	August									1	1
	September										
	October	1								2	2
	November									1	4
	December		2			1					2
2001	January										4
	February		1		1	2				1	3
	March								1	1	5
	April				1				1	1	4
	May					1	2		2		1
	June										1
	July										
	August								1		2
	September					1		1		1	
	October			2		1			1	1	1
	November	1								1	4
	December				2					3	3

Year	Month	Countries without routine MCC vaccination						Countries with routine MCC vaccination			
		Austria	Czech Republic	Denmark	France	Greece	Italy	Ireland	Netherlands	Spain	United Kingdom
2002	January				1			1		8	2
	February				1	1	1			6	2
	March		1							3	3
	April				1		1	1	1	3	
	May					1				2	3
	June									1	
	July									1	
	August	1							1		2
	September	1								2	1
	October									3	
	November	1									
	December	3							1	1	
2003	January	1			1					7	
	February	1								4	2
	March				1					6	
	April						1			4	
	May									2	2
	June										3
	July										1
	August										
	September									2	
	October									1	
	November									2	1
	December									2	1
2004	January				3		1		2	2	3
	February				1						1
	March		1					1		1	
	April				1					1	2
	May				1					2	
	June		2		1					1	1
	July		1		1						2
	August										
	September								1		
	October										
	November		1				1				
	December							1			

Shaded boxes indicate year of introduction of routine MCC vaccination

Table A21 Frequency of phenotype/genotype present in invasive meningococcal serogroup C isolates, by country, 2003

Present in more than 10 isolates														
	C:P2.2a: P1.5,2	C:P2.2a: P1.5,10	C:P2.2a: P1.5	C:P2.2a: P1.2	C:P2.2a: NST:NST	C:P2.2b: P1.5,2	C:P2.2b: P1.5	C:P2.2b: P1.2	C:P2.2b: NST:NST	C:P3.15: P1.7,16	C:NT: P1.5,2	C:NT: P1.5	C:NT: NT	Total listed (% total known)
Austria (A)			2		2	2		2	1				1	10 (83%)
Belgium (B)	14		10	2	4	6		1	1				3	41 (89%)
Czech Republic (CR)	10			8							3		1	22 (96%)
Denmark (D)	1				2	1		1	2	5	1		1	14 (74%)
Finland (Fi)									1				2	3 (60%)
France (Fr)	10		30	5	1	20		4			17	4	1	92 (95%)
Germany (Ge)	47	31				26								104 (86%)
Greece (Gr)		2												2 (100%)
Ireland (Ir)				1	1									2 (100%)
Italy (It)			9			2	25		5				5	46 (84%)
Malta (M)			1											1 (100%)
Netherlands (Ne)	7		15		5	3		2			2	4		38 (86%)
Norway (No)	3		1						1	1	1			7 (78%)
Poland (Pl)	1		1			6		1			1		3	13 (62%)
Portugal (Pt)			2			1	18	1	1					23 (82%)
Slovak Republic (SR)	8			2	1									11 (100%)
Slovenia (Sl)											1		2	3 (100%)
Spain (Sp)			57			7	4	1			4	1	1	75 (91%)
Sweden (Se)	1									5	1			7 (58%)
Switzerland (Si)	6		3	1	1	6		2	1					20 (87%)
United Kingdom (UK)	6		30	2	12	1						3	2	56 (86%)
Total	114	33	161	21	29	81	47	15	12	11	31	12	22	589 (86%)
Present in 2 – 9 isolates (Country)														
C:P2.2a:P1.7,1 (D, Fr, Ge, It)			C:P3.4:P1.7,16 (It, Se)			C:NT:P1.7,16 (Se)								
C:P2.2aP1.22,9 (Ge)			C:P3.4:P1.15 (Sp)			C:NT:P1.12 (Pl)								
C:P2.2a:P1.15 (B, Sp)			C:P3.4:NST:NST (D, It, UK)			C:NT:P1.19,15 (UK)								
C:P2.2b:P1.7,1 (B)			C:P3.4:P1.4 (It, Si)			C:NT:P1.2 (CR, Fr)								
			C:P3.14:P1.5,2 (Sp, Se)			C:NT:P1.3 (Pl, UK)								

No of isolates of each C:serotype:vr1:vr2 combination was determined, and the geographical distribution of each combination present in more than one isolate identified. Both genotypic and phenotypic data were analysed

Table A22 Frequency of phenotype/genotype present in invasive meningococcal serogroup C isolates, by country, 2004

Present in more than 10 isolates															
	C:P2.2a: P1.5,2	C:P2.2a: P1.5,10	C:P2.2a: P1.5	C:P2.2a: P1.2	C:P2.2a: NST:NST	C:P2.2b: P1.5,2	C:P2.2b: P1.5	C:P2.2b: P1.2	C:P2.2b: NST:NST	C:NT: P1.5,2	C:NT: P1.5	C:NT: P1.2	C:NT: P1.3	C:NT: NST:NST	Total listed (% total known)
Austria (A)			1		4			2				5		1	13 (93%)
Belgium (B)	4		4	2	2	3								1	16 (80%)
Czech Republic (CR)	8			11	2							2		2	25 (100%)
Denmark (D)			1		2	1	1		1						6 (43%)
Finland (Fi)									1				2		3 (60%)
France (Fr)	11		38	5	14	12	1	4	3	11	4	5		10	118 (91%)
Germany (Ge)	43	10				15									68 (91%)
Ireland (Ir)	1														1 (100%)
Italy (It)	1		4		1	41	9	4	12	2				2	76 (92%)
Netherlands (Ne)	2	4				5				1					12 (71%)
Poland (Pl)	1		1			12					2		8	4	28 (70%)
Portugal (Pt)							4		3		1				8 (100%)
Slovak Republic (SR)	1			2						1		1			5 (100%)
Spain (Sp)	1		15	1	5	1	1		1	1				3	29 (94%)
Sweden (Se)	1	1				1				2					5 (45%)
Switzerland (Si)	3		4	1	2	4		1	1					2	18 (100%)
United Kingdom (UK)	1		12		6	1				4	3			1	28 (85%)
Total	78	15	80	22	38	96	16	11	22	22	10	13	10	26	459 (87%)
Present in more than 2 - 9 isolates (Country)															
P2.2a:P1.22,9	(Ge)				P3.14:NST:NST		(Pl)			NT:P1.12,4				(A, Se)	
P2.2b:P1.5,4	(B)				P3.15:P1.7,16		(Se)			NT:P1.1				(It)	
P3.4:P1.9	(Pl)				P3.15:P1.7		(D)			NT:P1.4				(Pl, UK)	
P3.4:NST:NST	(It, Pl)				P3.15:P1.19,15		(Se)			NT:P1.9				(Pl, UK)	
					P3.15:NST:NST		(D)			NT:P1.16					

No of isolates of each C:serotype:vr1:vr2 combination was determined, and the geographical distribution of each combination present in more than one isolate identified. Both genotypic and phenotypic data were analysed

Table A23 Frequency of serosubtypes present in invasive meningococcal serogroup B isolates, by country, 2003

Present in more than 30 isolates																		
	B:P1.5 ,2	B:P1.5 ,10	B:P1.5	B:P1.7 ,4	B:P1.7 ,16	B:P1.7	B:P1.19 ,15	B:P1.22 ,14	B:P1.3	B:P1.4	B:P1.9	B:P1.10	B:P1.13	B:P1.14	B:P1.15	B:P1.16	B:NST: NST	Total listed (% total known)
Austria (A)	1		2		8	4			1	3			1	1	1	1	12	35 (95%)
Belgium (B)	10		3	2	4	4				86	2	5	6	6	9	2	18	157 (96%)
Czech Republic (CR)	2		5		1					1				2	3		5	19 (95%)
Denmark (D)	5		1		31				3		1		1	3	6	4	2	57 (100%)
Finland (Fi)	3		2	1	2	5			1	3	1			3	1		5	27 (96%)
France (Fr)	6		9		23	7				51	5	3	6	7	13	5	11	146 (89%)
Germany (Ge)	22	31		62	69		23	29				2	1	1				240 (70%)
Greece (Gr)	1	1		1	2	1	6	11			1			1				25 (89%)
Ireland (Ir)			1			1	4		1	20	1	1		6		2	7	44 (90%)
Italy (It)			8		4	2			3	16	1	2	9	3	2	5	11	66 (100%)
Malta (M)							3											3 (100%)
Netherlands (Ne)	8		4	2	9	6				107	7	22		29	19	12	64	289 (98%)
Norway (No)	1				5	3				13	1		1		2	3	6	35 (97%)
Poland (Pl)	1		2		3				2	2		2	1	9			5	27 (87%)
Portugal (Pt)			3		1	2				3			2	8	6		16	41 (91%)
Slovak Republic (SR)			1		1	2			1		1	1	1		2	3	10	23 (92%)
Slovenia (Sl)			1		1				2						1			5 (83%)
Spain (Sp)	8		35		4	10			5	35	32	3	12	34	144	19	41	382 (93%)
Sweden (Se)		2		3	3		4	1										13 (46%)
Switzerland (Si)	2		4		2				2	5		1		2		3	13	34 (100%)
United Kingdom (UK)	26	2	29	12	24	7	125	12	14	199	86	5	4	102	8	33	75	763 (91%)
Total	96	36	110	83	197	54	165	53	35	544	139	47	45	217	217	92	301	2431 (90%)
Present in between 30 and 10 isolates (Country)																		
B:P1.7,1	(A, Fr, Ge, Ne, Pl, Sp, UK)						B:P1.18,3	(Ge, Gr)			B:P1.22,9	(Ge, Se, UK)						
B:P1.7,13	(Fr, Ge, Se, UK)						B:P1.18,25	(Ge, Se, UK)						B:P1.1	(Fr, Ne, Pl, SR, Sp, UK)			
B:P1.12,13	(Fr, Ge, Sp, Se, UK)						B:P1.19,13	(Ge, Ir, UK)						B:P1.2	(A, B, Fr, SR, Sp, UK)			
B:P1.17,9	(Ge, Se)						B:P1.19	(Ir, UK)						B:P1.12	(B, Fi, Fr, Pl, Pt, Sl, Sp, UK)			
							B:P1.21,16	(Ge, Gr, Se, UK)										

<i>Present in between 9 and 2 isolates (Country)</i>					
B:P1.7,2	(Ge, UK,)	B:P1.12,4	(Ge,)	B:P1.18,9	(Ge,)
B:P1.7,9	(No, Pt, Sp,)	B:P1.12,9	(Sp, UK,)	B:P1.18,13	(Ge,)
B:P1.7,14	(B, CR, Ge, Pt, Sp,)	B:P1.12,16	(Ge,)	B:P1.19,2	(UK,)
B:P1.7,15	(Fr, UK,)	B:P1.17,16	(Ge, UK,)	B:P1.19,3	(UK,)
B:P1.7,30	(Ge, Se,)			B:P1.19,16	(UK,)

No of isolates of each B:vr1:vr2 combination was determined, and the geographical distribution of each combination present in more than one isolate identified. Both genotypic and phenotypic data were analysed

Table A24 Frequency of serosubtypes present in invasive meningococcal serogroup B isolates, by country, 2004

Present in more than 30 isolates																	
	B:P1.5, 2	B:P1.5, 10	B:P1.5	B:P1.7, 4	B:P1.7, 13	B:P1.7, 16	B:P1.7	B:P1.19 ,15	B:P1.22 ,14	B:P1.4	B:P1.9	B:P1.13	B:P1.14	B:P1.15	B:P1.16	B:NST: NST	Total listed (% total known)
Austria (A)						13	1				1		2	3		8	28 (88%)
Belgium (Be)	5		4	1		4	1			47	2	8	8	13	6	16	115 (94%)
Czech Republic (CR)	2		4			4							7	5	2	9	33 (85%)
Denmark (D)	2		1		1	28				2	2		5	8	2	2	53 (95%)
Finland (Fi)			3				3			4	1	1		2	1	9	24 (83%)
France (Fr)	3		10	1		19	10			68	11	7	12	2	8	70	221 (94%)
Germany (Ge)	14	27		82	8	49		18	26								224 (76%)
Greece (Gr)		1	3			4	3	2	3	3	2		3			1	25 (89%)
Ireland (Ir)			3					4		15	3	1	4	1	1	1	33 (75%)
Italy (It)	2		2			2				13	4	8		3	3	6	43 (91%)
Malta (M)								1		1							2 (50%)
Netherlands (Ne)	4	28		80	28	17		13	29				1				200 (85%)
Norway (No)	1					4	1			6	1			2	2		17 (100%)
Poland (Pl)	9		6	1		9	1			2		1	13		1	12	55 (77%)
Portugal (Pt)			4			1				7	3	1	5	3	1	24	49 (88%)
Slovak Republic (SR)							1						1	5		2	9 (64%)
Slovenia (Sl)	1					1				1						1	4 (80%)
Spain (Sp)	2		10				2			10	14	1	2	15	8	15	79 (94%)
Sweden (Se)		1		3	6	8		2	1								21 (78%)
Switzerland (Si)	1					2				8	4	1	4	3	5	5	33 (92%)
United Kingdom (UK)	19		27	17	1	14	8	101	14	163	85	8	67		23	71	618 (89%)
	65	57	77	185	44	179	31	141	73	350	133	37	134	65	63	252	1886 (87%)
Present in between 30 and 10 isolates (Country)																	
B:P1.7,1	(A, Be, CR, Ge, Ne, Pl, Pt, SR, UK)					B:P1.21,16	(Ge, Ne, UK)					B:P1.3	(A, Be, D, Fi, Ir, It, Pl, Sl, UK)				
B:P1.18,3	(Ge, Ne, Se, UK)					B:P1.22,9	(Ge, Ne, Se, UK)					B:P1.10	(A, Be, Fi, Fr, Ir, It, Pl, Sp, UK)				
B:P1.19,13	(Ge, Ir, Ne, UK)					B:P1.1	(D, Fr, It, Pt, SR, Sp, Si, UK)					B:P1.12	(CR, Fi, Fr, Pl, Pt, Sp, Si, UK)				
B:P1.19	(Ir, UK)																

Present in between 9 and 2 isolates (Country)					
B:P1.5,14	(Fr, Pl)	B:P1.17,9	(Ge, Ne)	B:P1.19,3	(M, UK)
B:P1.7,2	(Ge, Ne)	B:P1.17,16	(Ge)	B:P1.19,14	(Ne, UK)
B:P1.7,14	(Fi, UK)	B:P1.17,23	(Se, UK)	B:P1.19,16	(UK)
B:P1.7,30	(Ge, Ne)	B:P1.18,2	(Ge)	B:P1.31,16	(Ne)
B:P1.12,4	(Ge, Ne, Pl)	B:P1.18,9	(Ge, Ne, Se)	B:P1.2	(CR, Fr, Gr, UK)
B:P1.12,13	(D, Fr, Ge, Ne, UK)	B:P1.18,25	(Ne, Se, UK)	B:P1.14	(Pt)
B:P1.12,16	(Ge)	B:P1.18,30	(Ge, Ne)		
B:P1.12,4	(Ge, Ne, Pl)				

No of isolates of each B:vr1:vr2 combination was determined, and the geographical distribution of each combination present in more than one isolate identified.
Both genotypic and phenotypic data were analysed

Table A25 Case fatality ratio in confirmed and probable laboratory-diagnosed cases of meningococcal disease, by country, 1999 – 2004

	1999			2000			2001			2002			2003			2004		
	Deaths	Cases	Case fatality	Deaths	Cases	Case fatality	Deaths	Cases	Case fatality	Deaths	Cases	Case fatality	Deaths	Cases	Case fatality	Deaths	Cases	Case fatality
Austria	7	97	7.22%	5	83	6.02%	7	106	6.60%	6	81	7.41%	5	73	6.85%	7	70	10.00%
Belgium	16	297	5.39%	13	267	4.87%	27	380	7.11%	15	262	5.73%	9	228	3.95%	10	157	6.37%
Czech Republic	7	93	7.53%	5	61	8.20%	10	93	10.75%	18	113	15.93%	8	92	8.70%	16	96	16.67%
Denmark	14	177	7.91%	11	151	7.28%	10	161	6.21%	7	98	7.14%	8	103	7.77%	5	98	5.10%
Estonia	1	3	33.33%	0	9	0.00%	2	20	10.00%	0	8	0.00%	0	8	0.00%	4	11	36.36%
Finland	10	57	17.54%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
France	35	411	8.52%	59	489	12.07%	73	559	13.06%	94	648	14.51%	63	650	9.69%	70	625	11.20%
Germany	-	-	-	-	-	-	53	770	6.88%	67	730	9.18%	68	768	8.85%	47	596	7.89%
Greece	8	130	6.15%	11	174	6.32%	7	185	3.78%	8	196	4.08%	3	119	2.52%	2	72	2.78%
Hungary	-	-	-	-	-	-	-	-	-	-	-	-	6	41	14.63%	9	43	20.93%
Iceland	2	21	9.52%	2	18	11.11%	2	19	10.53%	1	15	6.67%	0	8	0.00%	1	10	10.00%
Ireland	17	445	3.82%	25	411	6.08%	12	297	4.04%	8	225	3.56%	12	221	5.43%	8	176	4.55%
Italy	13	254	5.12%	20	243	8.23%	14	201	6.97%	24	214	11.21%	22	271	8.12%	30	314	9.55%
Latvia	-	-	-	-	-	-	-	-	-	-	-	-	4	16	25.00%	3	23	13.04%
Lithuania	-	-	-	-	-	-	2	35	5.71%	3	29	10.34%	4	30	13.33%	4	53	7.55%
Malta	5	17	29.41%	3	20	15.00%	0	13	0.00%	2	14	14.29%	0	16	0.00%	3	13	23.08%
Netherlands	23	576	3.99%	29	542	5.35%	41	721	5.69%	24	616	3.90%	8	354	2.26%	13	278	4.68%
Norway	9	77	11.69%	7	85	8.24%	3	77	3.90%	5	51	9.80%	5	51	9.80%	3	34	8.82%
Poland	1	67	1.49%	0	43	0.00%	2	37	5.41%	0	35	0.00%	8	57	14.04%	8	116	6.90%
Portugal	-	-	-	-	-	-	-	-	-	6	185	3.24%	11	140	7.86%	5	124	4.03%
Slovak Republic	-	-	-	-	-	-	-	-	-	-	-	-	5	49	10.20%	2	32	6.25%
Slovenia	0	6	0.00%	2	8	25.00%	2	10	20.00%	1	8	12.50%	1	16	6.25%	0	9	0.00%
Spain	74	947	7.81%	-	-	-	59	643	9.18%	107	834	12.83%	-	-	-	84	696	12.07%
Sweden	-	-	-	-	-	-	-	-	-	9	46	19.57%	9	55	16.36%	5	56	8.93%
Switzerland	11	150	7.33%	10	149	6.71%	11	147	7.48%	15	91	16.48%	4	75	5.33%	5	79	6.33%
United Kingdom	219	3064	7.15%	230	2993	7.68%	211	2570	8.21%	130	1948	6.67%	107	1807	5.92%	77	1474	5.22%
Total	472	6889	6.85%	432	5746	7.52%	548	7044	7.78%	550	6447	8.53%	370	5248	7.05%	421	5255	8.01%

Table A26 Serogroup-specific case fatality rate in confirmed and probable laboratory-diagnosed cases of meningococcal disease, by country, 1999 – 2004 combined

Country	C deaths	C cases	C case fatality	B deaths	B cases	B case fatality	Other deaths	Other cases	Other case fatality
Austria	6	143	4.20%	29	394	7.36%	4	30	13.33%
Belgium	46	498	9.24%	41	988	4.15%	2	44	4.55%
Czech Republic	29	190	15.26%	24	294	8.16%	6	30	20.00%
Denmark	12	117	10.26%	40	511	7.83%	2	26	7.69%
Estonia	0	7	0.00%	2	31	6.45%	1	8	12.50%
Finland	2	9	22.22%	6	35	17.14%	1	9	11.11%
France	155	917	16.90%	143	1691	8.46%	50	277	18.05%
Germany	134	1425	9.40%	264	3779	6.99%	27	415	6.51%
Greece	9	75	12.00%	22	388	5.67%	3	301	1.00%
Iceland	3	49	6.12%	3	33	9.09%	2	3	66.67%
Ireland	21	333	6.31%	59	1363	4.33%	2	64	3.13%
Italy	43	297	14.48%	45	484	9.30%	2	21	9.52%
Netherlands	33	755	4.37%	102	2224	4.59%	3	94	3.19%
Norway	4	65	6.15%	27	260	10.38%	1	43	2.33%
Poland	3	92	3.26%	11	246	4.47%	3	14	21.43%
Portugal	5	143	3.50%	13	221	5.88%	3	28	10.71%
Slovenia	1	6	16.67%	2	37	5.41%	3	14	21.43%
Spain	144	867	16.61%	160	2002	7.99%	13	138	9.42%
Sweden	9	51	17.65%	12	107	11.21%	6	33	18.18%
Switzerland	23	289	7.96%	19	266	7.14%	6	57	10.53%
United Kingdom	362	2582	14.02%	504	9450	5.33%	85	776	10.95%
Total	1044	8910	11.72%	1528	24804	6.16%	225	2425	9.28%

Table A27 Proportion of meningitis in confirmed and probable laboratory-diagnosed cases of invasive meningococcal disease, 1999 – 2004

% meningitis	1999	2000	2001	2002	2003	2004
< 50%	Greece	Ireland	Ireland	Ireland	Lithuania	Iceland
	Ireland	United Kingdom	United Kingdom	Spain	Sweden	Ireland
	Malta			Sweden		Malta
	United Kingdom			United Kingdom		Spain
50% - 70%	Belgium	Belgium	Belgium	Belgium	Austria	Austria
	Estonia	Finland	Finland	Denmark	Belgium	Belgium
	Iceland	Greece	Iceland	Finland	Denmark	Czech Republic
	Netherlands	Iceland	Lithuania	France	Finland	Finland
	Norway	Malta	Norway	Malta	Iceland	Greece
	Slovenia		Spain	Netherlands	Ireland	Latvia
	Spain			Norway	Latvia	Lithuania
				Portugal	Malta	Netherlands
				Slovenia	Netherlands	Norway
				Switzerland	Poland	Slovenia
					Spain	Sweden
					United Kingdom	United Kingdom
	> 70%	Austria	Austria	Austria	Austria	Czech Republic
Czech Republic		Czech Republic	Czech Republic	Czech Republic	Estonia	Estonia
Denmark		Denmark	Denmark	Estonia	France	France
Finland		Estonia	Estonia	Greece	Greece	Hungary
France		France	France	Iceland	Hungary	Italy
Italy		Italy	Greece	Italy	Italy	Poland
Poland		Netherlands	Italy	Lithuania	Norway	Portugal
Switzerland		Norway	Malta	Poland	Portugal	Slovak Republic
		Poland	Netherlands		Slovak Republic	Switzerland
		Slovenia	Poland		Slovenia	
		Spain	Portugal		Switzerland	
		Switzerland	Slovenia			
			Switzerland			